Princeton, New Jersey, August 17, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in intensive care units and cardiac surgery using blood purification with proprietary polymer adsorption technology, and the Israeli Ministry of Health (MoH) has has approved national reimbursement of CytoSorb® in certain cardiac surgery indications, expected to take effect in 2023.
Specifically, the Israeli Ministry of Health’s Hospital Technical Committee has approved CytoSorb reimbursement in the country, also known as “addition to the healthcare basket”, for the following indications:
- Intraoperative treatment of emergency or emergency cardiac surgery in patients treated with ticagrelor or rivaroxaban
- Intraoperative treatment during cardiac surgery in patients with acute infective endocarditis
- Intraoperative treatment during correction of aortic dissection
With that decision, the committee recognizes the importance and value of CytoSorb for intraoperative removal of various antithrombotic agents and inflammatory mediators during cardiac surgery. Public hospitals are expected to receive her CytoSorb reimbursement for these applications once the policy revision is complete.
Christian SteinerCytoSorbents’ executive vice president of sales and marketing, MD, said:Israel has one of the highest quality and advanced healthcare systems in the world, strengthened by leadership in the adoption of innovative medical technologies. We are pleased that the Ministry of Health has recognized the benefits of intraoperative CytoSorb use in cardiac surgery and approved national reimbursement. ”
Israel It has a population of about 9 million people, all of whom have universal health insurance. Each year, the country spends about 7.5% of its Gross Domestic Product (GDP) on healthcare. Israel use a quote $2.4 billion Imports account for approximately 65% of the medical device market. Heart disease is her second leading cause of death in the country, according to the Israel Heart Association. More than 4,000 heart surgeries have been performed. Israel every year.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in treating life-threatening conditions in critical care and cardiac surgery with blood purification. His flagship product, CytoSorb®, is approved in the European Union and sold in over 70 countries worldwide. This is an extracorporeal cytokine designed to reduce the “cytokine storm” or “cytokine release syndrome” that occurs in common critical illnesses and can lead to massive inflammation, organ failure and patient death. Adsorbent. These diseases can pose a very high risk of death and have few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications such as multi-organ failure.Current June 30, 2022, with more than 179,000 CytoSorb devices in cumulative use worldwide. CytoSorb was first launched in the European Union under his CE mark as the first in vitro cytokine adsorbent. Additional CE mark extensions were granted for bilirubin and myoglobin ablation in clinical conditions such as liver disease and trauma, and for ticagrelor and rivaroxaban ablation during cardiothoracic surgery, respectively. CytoSorb has also received emergency FDA approval. usa For use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. Based on the same polymer technology as CytoSorb, the DrugSorb™-ATR antithrombectomy system has FDA breakthrough device designation for removing ticagrelor and the direct oral anticoagulants (DOACs) apixaban and rivaroxaban in the cardiopulmonary bypass circuit. also received FDA Breakthrough Device designation. Emergency cardiothoracic procedure. The company has initiated two of his pivotal FDA-approved studies to support marketing approval of DrugSorb-ATR in the United States. The first was a randomized study of 120 patients at 30 centers to assess whether intraoperative use of DrugSorb-ATR could reduce perioperative bleeding risk in ticagrelor patients undergoing cardiothoracic surgery. Controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) trial. The second study Star D Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants Intraoperative use of DrugSorb-ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery who are taking direct oral anticoagulants such as apixaban and rivaroxaban. Randomized controlled trial of 120 patients at 30 centers evaluating .
CytoSorbents’ purification technology is based on highly porous biocompatible polymeric beads that can actively remove toxic substances from blood and other bodily fluids through pore entrapment and surface adsorption. Our technology is $39.5 million DARPA, U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), undiluted grants, contracts, and other funding from the U.S. Army, U.S. Air Force, U.S. Specialty Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), etc. Based on this proprietary blood purification technology, the company is protected by numerous issued U.S. and international patents and registered trademarks, and several pending patent applications, including ECOS-300CY®, CytoSorb-XL™ and HemoDefend- We have a number of commercial and developmental products that are being developed. RBC™, HemoDefend-BGA™, VetResQ®, K+ ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, etc.For more information, visit the company’s websites www.cytosorbents.com and www.cytosorb.com, or follow us on Facebook and www.cytosorbents.com. twitter.
This press release contains forward-looking statements within the safe harbor of the Private Securities Litigation Reform Act of 1995.business, expectations about the future impact of COVID-19, or ongoing disputes Russia When Ukraine, statements and claims, not historical facts, generally “could”, “should”, “could”, “expect”, “plan”, “anticipate” , identified by the use of words such as “believe”. “forecast”, “prediction”, “probability”, “continuation” and similar terms; Although the forward-looking statements in this press release reflect management’s current beliefs and expectations, actual results, events and performance may differ materially from the forward-looking statements. Please note. Factors that could cause or contribute to such differences include, but are not limited to, the risks disclosed in our Annual Report on Form 10-K filed with the SEC. not. March 10, 2022, quarterly reports on Form 10-Q, press releases and other communications to stockholders that we issue from time to time to inform our stakeholders of the risks and factors that may affect our business. You are cautioned not to place undue reliance on such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.
Click to follow us on Facebook. twitter
US company contact:
305 College Road East
Princeton, New Jersey 08540
+1 (732) 329-8885
European company contact:
+49 30 765 84 66 23
rubenstein public relations
+49 69 13823 ext.960
+49 172 4238938
Source: CytoSorbents Corporation